EFFICACY OF BRENTUXIMAB VEDOTIN AND OTHER TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA (SALCL): A SYSTEMATIC REVIEW

被引：0

作者：

Hamashima, C. ^{[1
]}

Ogoshi, K. ^{[2
]}

Okamoto, M. ^{[3
]}

Shabana, M. ^{[4
]}

Kishimoto, T. ^{[3
]}

Fukao, A. ^{[5
]}

机构：

[1] Natl Canc Ctr Japan, Tokyo, Japan

[2] Niigata Canc Ctr Hosp, Niigata, Japan

[3] Tottori Univ, Yonago, Tottori, Japan

[4] San in Rosai Hosp, Yonago, Tottori, Japan

[5] Yamagata Univ, Yamagata 990, Japan

来源：

VALUE IN HEALTH | 2013年 / 16卷 / 07期

关键词：

D O I：

10.1016/j.jval.2013.08.417

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A395 / A395

页数：1

共 50 条

[41] Systemic anaplastic large-cell Lymphoma (sALCL) 5-Year-Data with Brentuximab Vedotine signals Chance of Healing
不详
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (03) : 155 - 155
[42] REAL LIFE EXPERIENCE WITH BRENTUXIMAB VEDOTIN: THE ITALIAN STUDY ON 40 RELAPSED/REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA PATIENTS
Quirini, F.
Broccoli, A.
Pellegrini, C.
Di Rocco, A.
Puccini, B.
Patti, C.
Gini, G.
Mannina, D.
Tani, M.
Rusconi, C.
Romano, A.
Vanazzi, A.
Botto, B.
Carlo-Stella, C.
Hoaus, S.
Musto, P.
Mazza, P.
Molica, S.
Corradini, P.
Fama, A.
Gaudio, F.
Merli, M.
Gravetti, A.
Gritti, G.
Arcari, A.
Tosi, P.
Liberati, A. M.
Pinto, A.
Pavone, V.
Gherlinzoni, F.
Naso, V.
Volpetti, S.
Trentin, L.
Goldaniga, M. C.
Bonfichi, M.
De Renzo, A.
Schiavotto, C.
Spina, M.
Storti, S.
Carella, A. M.
Stefoni, V.
Argnani, L.
Zinzani, P. L.
HAEMATOLOGICA, 2017, 102 : 50 - 51
[43] Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin
Zinzani, Pier Luigi
Derenzini, Enrico
Pellegrini, Cinzia
Celli, Monica
Broccoli, Alessandro
Argnani, Lisa
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (05) : 681 - 683
[44] Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Song, Yuqin
Guo, Ye
Huang, Huiqiang
Li, Wei
Ke, Xiaoyan
Feng, Jifeng
Xu, Wei
Miao, Harry
Kinley, Judith
Song, Gregory
Dai, Yi
Wang, Hui
Zhu, Jun
EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (09) : 867 - 875
[45] Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
Izutsu, Koji
Ogura, Michinori
Tobinai, Kensei
Hatake, Kiyohiko
Sakamoto, Shigeru
Nishimura, Masanori
Hoshino, Miyako
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 404 - 412
[46] Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
Koji Izutsu
Michinori Ogura
Kensei Tobinai
Kiyohiko Hatake
Shigeru Sakamoto
Masanori Nishimura
Miyako Hoshino
International Journal of Hematology, 2021, 113 : 404 - 412
[47] Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
Chen, Robert
Allibone, Suzanne
Bartlett, Nancy L.
Brice, Pauline
Chen, Andy
Pose, Katrina
Rich, Lynn
Bonthapally, Vijay
Garfin, Phillip M.
Fanale, Michelle
ONCOTARGETS AND THERAPY, 2016, 9 : 2027 - 2034
[48] Extended use of brentuximab vedotin before autologous stem-cell transplantation would benefit refractory systemic anaplastic large-cell lymphoma
Koh, Youngil
CLINICAL CASE REPORTS, 2018, 6 (05): : 798 - 801
[49] RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA (ALCL) - A BURDEN OF ILLNESS ANALYSIS
Baculea, S.
Eaton, J.
Illidge, T.
HAEMATOLOGICA, 2012, 97 : 103 - 104
[50] Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma
Alderuccio, Juan Pablo
Desai, Amrita
Yepes, Monica M.
Chapman, Jennifer R.
Vega, Francisco
Lossos, Izidore S.
CLINICAL CASE REPORTS, 2018, 6 (04): : 634 - 637

← 1 2 3 4 5 →